Business Context and Reporting Period
This Form 8-K filing by Aldeyra Therapeutics, Inc. (ALDX) reports a corporate governance event dated January 13, 2020, with the report filed on January 14, 2020. The filing details the election of a new director and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report focused on personnel changes rather than financial performance.
Material Changes
- Board Composition: The Board of Directors increased the number of directors to eight.
- Director Election: Nancy Miller-Rich was elected as a Class I director, with her term expiring at the 2021 annual meeting of stockholders.
- Independence: The Board determined Ms. Miller-Rich to be an independent director.
Compensation and Governance Details
In connection with her election, Ms. Miller-Rich received the following compensatory arrangements:
- Initial Stock Option: Granted a non-statutory stock option to purchase 24,264 shares of common stock. The exercise price equals the closing stock price on January 13, 2020. The option vests ratably in annual installments over three years.
- Annual Cash Fee: An annual fee of $30,000 for service as a director.
- Annual Stock Option Grant: Eligible to receive an annual option to purchase approximately $86,000 of common stock upon the conclusion of each annual meeting. These grants vest in full on the one-year anniversary of the grant date.
- Indemnification: Ms. Miller-Rich entered into an indemnification agreement requiring the company to indemnify her to the fullest extent permitted under Delaware law.
Investor Verification Checklist
- Verify the closing stock price of ALDX on January 13, 2020, to determine the exercise price of the initial 24,264 share option grant.
- Review the attached Press Release (Exhibit 99.1) for additional context on the director's background.
- Confirm the total number of directors is now eight as stated in the filing.
- Check the company's Proxy Statement for the 2019 Annual Meeting for the full details of the non-employee director compensation program.